Table 1.
Study site characteristics
| Site characteristics | Study Site | |||
|---|---|---|---|---|
| Site A | Site B | Site C | Site D | |
| Client gender identity (%) | ||||
| Female | 31.5 | 27.7 | 32.6 | 47.9 |
| Male | 67.4 | 70.1 | 67.4 | 51.7 |
| Transgender | 0.2 | 0.2 | -- | 0.2 |
| Nonbinary | 0.4 | -- | -- | 0 |
| Othera | 0.4 | 2.2 | -- | 0.2 |
| Client racial identity (%) | ||||
| American Indian/Native American | 1.8 | 0.1 | 0.2 | 0.6 |
| Asian/Pacific Islander | 1.1 | 1.0 | 0.4 | 2.5 |
| Black/African-American | 10.3 | 24.9 | 32.9 | 6.9 |
| White/Caucasian | 76.6 | 43.2 | 41.6 | 66.9 |
| Otherb | 10.0 | -- | 21.5 | 23.0 |
| Client ethnic identity (%) | ||||
| Hispanic/Latino/Latinx/Latine | 27.4 | 29.1c | 21.5c | 14.7 |
| Number of new clients in 2021 | -- | 952 | 392 | 6081 |
| Number of HIV tests performed | 350 | 20 | 360 | 890 |
| Number of clients with opioid use disorder | 117 | -- | 1133 | 3159 |
| Presence of the following services (yes/no): | ||||
| On site HIV testing | Yes | Yes | Yes | Yes |
| On site PrEPd | Yes | No | No | Yes |
| On site medications to treat opioid use disorder (e.g.e.g., methadone, buprenorphine, naltrexone) | Yes | No | Yes | Yes |
| On site syringe exchange | Yes | Yes | No | Yes |
| On site naloxone provision and overdose education | Yes | Yes | Yes | Yes |
| Outreach services | Yes | Yes | Yes | Yes |
| Number of clinicians on site | 7 | 1 | 4 | 23 |
| Number of counselors/staff | 10 | 5 | 25 | 327 |
a
Other category includes: not asked, prefer not to disclose, questioning/unsure
b
Other category includes: do not know, more than one race, declined to answer, not asked, Middle Eastern or North African
c
Ethnic identity question was combined with racial identity question for this site
d
PrEP: Pre-exposure Prophylaxis
*
-- indicates that the data was not available